Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 1
2008 1
2016 1
2017 2
2018 2
2019 5
2020 3
2021 2
2022 2
2023 5
2024 12
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
N-terminal pro-brain natriuretic peptide is associated with pulmonary hypertension or diastolic dysfunction in patients with systemic sclerosis: An Australian prospective cross-sectional study.
Ha FJ, Brown Z, Stevens W, Prior D, Ross L, Ferdowsi N, Nikpour M, Burns AT. Ha FJ, et al. Among authors: ferdowsi n. J Scleroderma Relat Disord. 2024 Oct;9(3):178-184. doi: 10.1177/23971983241249209. Epub 2024 May 9. J Scleroderma Relat Disord. 2024. PMID: 39381051
The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes.
Quinlivan A, Neuen D, Hansen D, Stevens W, Ross L, Ferdowsi N, Proudman SM, Walker JG, Sahhar J, Ngian GS, Apostolopoulos D, Host LV, Major G, Basnayake C, Morrisroe K, Nikpour M. Quinlivan A, et al. Among authors: ferdowsi n. Arthritis Res Ther. 2024 Jun 25;26(1):124. doi: 10.1186/s13075-024-03355-0. Arthritis Res Ther. 2024. PMID: 38918847 Free PMC article.
Outcomes of Patients With Diffuse Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation Treated With Conventional Therapy.
Gregory K, Hansen D, Penglase R, Apostolopoulos D, Ngian GS, Stevens W, Morrisroe K, Ferdowsi N, Ross L, Walker J, Cooley H, Youssef P, Tymms K, Host L, Proudman S, Moore J, Nikpour M, Sahhar J. Gregory K, et al. Among authors: ferdowsi n. Arthritis Rheumatol. 2024 Aug;76(8):1294-1302. doi: 10.1002/art.42850. Epub 2024 May 8. Arthritis Rheumatol. 2024. PMID: 38560777
Measures of disease status in systemic sclerosis: A systematic review.
Tay T, Ferdowsi N, Baron M, Stevens W, Hudson M, Proudman SM, Nikpour M; Damage Index Working Group of the Scleroderma Clinical Trials Consortium. Tay T, et al. Among authors: ferdowsi n. Semin Arthritis Rheum. 2017 Feb;46(4):473-487. doi: 10.1016/j.semarthrit.2016.07.010. Epub 2016 Jul 29. Semin Arthritis Rheum. 2017. PMID: 27765344 Review.
Multidisciplinary team discussion: the emerging gold standard for management of cardiopulmonary complications of connective tissue disease.
Fairley JL, Ross L, Burns A, Prior D, Conron M, Rouse H, McDonald J, MacIsaac A, La Gerche A, Morrisroe K, Ferdowsi N, Quinlivan A, Brown Z, Stevens W, Nikpour M. Fairley JL, et al. Among authors: ferdowsi n. Intern Med J. 2023 Oct;53(10):1919-1924. doi: 10.1111/imj.16233. Epub 2023 Sep 29. Intern Med J. 2023. PMID: 37772776 Free PMC article. Review.
Clinical characteristics and survival of pulmonary arterial hypertension with or without interstitial lung disease in systemic sclerosis.
Fairley JL, Hansen D, Ross L, Proudman S, Sahhar J, Ngian GS, Walker J, Host LV, Morrisroe K, Apostolopoulous D, Ferdowsi N, Wilson M, Tabesh M, Stevens W, Nikpour M; Australian Scleroderma Interest Group. Fairley JL, et al. Among authors: ferdowsi n. Arthritis Res Ther. 2023 May 12;25(1):77. doi: 10.1186/s13075-023-03059-x. Arthritis Res Ther. 2023. PMID: 37173780 Free PMC article.
Evaluation of the European Society of Cardiology Risk Assessment Score in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
Brown Z, Hansen D, Stevens W, Ferdowsi N, Ross L, Quinlivan A, Sahhar J, Ngian GS, Apostolopoulos D, Walker JG, Proudman S, Teng GG, Low AHL, Morrisroe K, Nikpour M. Brown Z, et al. Among authors: ferdowsi n. Arthritis Care Res (Hoboken). 2024 Jul;76(7):973-983. doi: 10.1002/acr.25328. Epub 2024 Apr 22. Arthritis Care Res (Hoboken). 2024. PMID: 38523256
Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index.
Ross L, Hansen D, Proudman S, Khanna D, Herrick AL, Stevens W, Baron M, Nikpour M; Australian Scleroderma Interest Group (ASIG), Canadian Scleroderma Research Group (CSRG), the Scleroderma Clinical Trials Consortium Activity Index Working Group. Ross L, et al. Arthritis Rheumatol. 2024 Nov;76(11):1635-1644. doi: 10.1002/art.42939. Epub 2024 Aug 26. Arthritis Rheumatol. 2024. PMID: 38937146
Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.
Ferdowsi N, Huq M, Stevens W, Hudson M, Wang M, Tay T, Burchell JL, Mancuso S, Rabusa C, Sundararajan V, Prior D, Proudman SM, Baron M, Nikpour M; Scleroderma Clinical Trials Consortium Damage Index Working Group, The Australian Scleroderma Interest Group, Canadian Scleroderma Research Group; Scleroderma Clinical Trials Consortium Damage Index Working Group, TheAustralian Scleroderma Interest Group, Canadian Scleroderma Research Group. Ferdowsi N, et al. Ann Rheum Dis. 2019 Jun;78(6):807-816. doi: 10.1136/annrheumdis-2018-214764. Epub 2019 Mar 30. Ann Rheum Dis. 2019. PMID: 30928903
Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling.
Barbacki A, Baron M, Wang M, Zhang Y, Stevens W, Sahhar J, Proudman S, Nikpour M, Man A; Australian Scleroderma Interest Group and the Canadian Scleroderma Research Group. Barbacki A, et al. Arthritis Care Res (Hoboken). 2023 Mar;75(3):640-647. doi: 10.1002/acr.24873. Epub 2022 Nov 15. Arthritis Care Res (Hoboken). 2023. PMID: 35226416
32 results